Abstract 1368P
Background
Molecular testing for biomarkers in patients (pts) with advanced/metastatic NSCLC (a/mNSCLC) is essential for diagnostic testing and use of targeted therapy. Testing patterns across lines of therapy (LOT) for pts with a/mNSCLC remain unclear.
Methods
This retrospective real-world study used ConcertAI Patient360™ database to assess biomarker testing patterns among adults with nonsquamous a/mNSCLC (2017–2022). Eligible pts received ≥1 LOT with ≥90-day follow-up. Biopsy and biomarker testing assessed actionable genetic alterations (ALK, BRAF, EGFR, KRAS, NTRK, RET, ROS1) and PD-L1 by LOT (first-, second-, third-line [1L, 2L, 3L]), test modality (IHC, FISH, CISH, NGS, PCR), and sample type (tissue/liquid).
Results
4528 pts were included; median age 67 years and from a community setting (76%). NGS rate at 1L was 57% overall (2017–2022) and increased to 80% during 2020–2022. Testing for ≥1 biomarker was 85% (1L), 31% (2L), 26% (3L) (overall, 2017–2022); and 89% (1L), 37% (2L), 28% (3L) (2020–2022). EGFR, BRAF, KRAS, RET, and ROS1 (Table) were mostly tested using NGS (56% at 1L vs 51% IHC, 21% FISH, and 10% PCR). Testing was most often conducted with tissue at 1L (64%) and liquid in 2L+ (41% each of tested 2L pts and 3L pts). At 2L, only 6% of pts had tissue re-biopsy, which dropped to 4% in 3L. Pts with 1L targeted therapy had higher re-testing (41% vs 25%, P<0.001) rates regardless of sample type in 2L than those who did not. Table: 1368P
N | Any biomarker (%) | PD-L1 (%) | ALK (%) | BRAF (%) | EGFR (%) | KRAS (%) | METexon14 (%) | NTRK (%) | RET (%) | ROS1 (%) | |
1L | 4528 | 85 | 71 | 73 | 65 | 78 | 64 | 46 | 40 | 55 | 71 |
2L | 1394 | 31 | 19 | 24 | 23 | 26 | 22 | 19 | 15 | 21 | 24 |
3L | 473 | 26 | 14 | 20 | 20 | 22 | 19 | 16 | 11 | 18 | 21 |
Conclusions
Tissue was most frequently used in 1L for biomarker testing by NGS for genetic alterations or IHC for PD-L1; however, tissue was not regularly re-biopsied in 2L+ settings. Biomarker testing rates drop as pts navigate through LOT. Re-testing rate is higher among pts with an actionable mutation in 1L. Standardization of biomarker testing post-1L is needed to facilitate optimal later-line treatment decisions and individualized care for pts with a/mNSCLC.
Clinical trial identification
Editorial acknowledgement
Medical writing support was provided by Hayley Ellis, PhD, of Fishawack Facilitate Ltd, part of Fishawack Health, funded by AbbVie.
Legal entity responsible for the study
AbbVie.
Funding
AbbVie funded this real-world study and participated in the study design, research, analysis, interpretation of data, and the review and approval of the publication. All authors had access to relevant data and participated in the drafting, review, and approval of this publication. No honoraria or payments were made for authorship.
Disclosure
C. Aggarwal: Financial Interests, Institutional, Research Funding: AstraZeneca, Genentech, Incyte, Macrogenics, Merck Sharp & Dohme, MedImmune; Financial Interests, Institutional, Funding, Consultation fees: Genentech, Lilly, Celgene Merck, AstraZeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/AstraZeneca, Regeneron/Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, Boehringer Ingelheim. Q. Xu, S. Ng, R. Kamalakar, S.A. Crawford, S. Beruti, A. Myftiu: Financial Interests, Personal, Full or part-time Employment: AbbVie; Financial Interests, Personal and Institutional, Stocks/Shares: AbbVie. M.B. Beasley: Financial Interests, Institutional, Advisory Board: AbbVie, AstraZeneca, Daiichi Sankyo.
Resources from the same session
1423P - Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy
Presenter: Anita Bolina
Session: Poster session 20
1424P - Outcome of thromboembolic events and its influence on survival time of advanced NSCLC patients receiving antiangiogenic therapy
Presenter: Wei-Fan Ou
Session: Poster session 20
1425P - Clinical utility of liquid biopsy for the early diagnosis of EGFR mutant advanced lung cancer in real-life setting (CLEAR)
Presenter: Rola El Sayed
Session: Poster session 20
1427P - Exploration of the value of leptomeningeal biopsy in diagnosing and treating non-small cell lung cancer with leptomeningeal metastasis
Presenter: Lin Cai
Session: Poster session 20
1428P - Clinical benefit of combination chemo-immunotherapy in first-line treatment for patients over the age of 65 or 75 with metastatic NSCLC
Presenter: Thierry Landre
Session: Poster session 20
1429P - Homologous recombination repair (HRR) gene mutation: A novel biomarker for precision genomics testing in advanced lung cancer
Presenter: Madhu Nagaraj
Session: Poster session 20
1430P - Excellent performance of a fast and fully-automated RNA based genefusion assay conducted on a large fusion positive non-small cell lung cancer cohort within a multicenter study
Presenter: Arndt Hartmann
Session: Poster session 20
1431P - The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance
Presenter: Martin Ziegler
Session: Poster session 20
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20